TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  Investing.com

CorMedix Builds a Real Revenue Story as DefenCath Adoption Accelerates

Investing.com Logo Investing.com • •By Nathan Reiff
CorMedix Builds a Real Revenue Story as DefenCath Adoption Accelerates

CorMedix is experiencing strong commercial momentum with its DefenCath catheter lock solution, which has shown a 72% reduction in catheter-related bloodstream infections in real-world evidence studies. The company reported Q3 2025 net revenue of $104.3 million and raised full-year guidance to $390-410 million. DefenCath adoption is outpacing expectations, and the Melinta Therapeutics acquisition adds diversification. Analysts are optimistic with nearly-unanimous Buy ratings and see 48% upside potential, though risks include pricing pressure and pipeline concentration.

Insights
CRMD   positive

Strong commercial execution with DefenCath adoption exceeding targets, significant revenue growth ($104.3M Q3 2025), raised full-year guidance, impressive adjusted EBITDA improvement ($72M vs -$2M prior year), strategic acquisition of Melinta adding revenue diversification, nearly-unanimous Wall Street Buy ratings, and promising Phase III pipeline data expected in Q2 2026. Stock has already gained 51% YTD with analysts seeing 48% additional upside.

Keywords
#DefenCath #catheter lock solution #dialysis infections #real-world evidence #commercial adoption #Melinta Therapeutics acquisition #REZZAYO #Phase III trial #revenue growth #EBITDA expansion

Tickers
CRMD
← Prev: Movement dan KAST Buka Akses Bayar dengan Stablecoin di Lebih dari 150 Juta Merchant Global, dengan Reward 4%